Twist Bioscience Raises $37 Million in Oversubscribed Series C Financing

June 10, 2015

— Proceeds to Accelerate Commercial Scaling of Silicon-Based Synthetic Biology Product Offering and to Pursue Strategic Opportunities –

— Investor Syndicate Includes Illumina and Top Institutional Healthcare Funds –

— Nicholas J. Naclerio, Ph.D., of Illumina, Joins the Twist Board of Directors —

SAN FRANCISCO, Calif. – June 9, 2015 – Twist Bioscience, a company focused on synthetic DNA, today announced the completion of a $37 million Series C financing. Led by Illumina, Inc., participants in the round include new investors Fidelity Management and Research Company and Foresite Capital Management LLC, as well as all existing investors including Nick and Joby Pritzker (through their family's firm Tao Invest), ARCH Venture Partners, Paladin Capital Group, Yuri Milner, and additional strategic corporate and venture investors. Since the company's founding in 2013, Twist Bioscience has raised a total of $82.1 million.

"Working with a select group of customers following our alpha manufacturing launch in April, we are now focused on validating the fit between our proprietary product offering and the wide variety of customer needs for synthetic DNA," said Emily Leproust, Ph.D., chief executive officer of Twist Bioscience. "This funding will allow us to accelerate into a beta commercial launch this fall. In addition, we intend to pursue strategic opportunities to add product capabilities and services to further enhance the Twist Bioscience user experience."

In conjunction with the financing Nicholas J. Naclerio, Ph.D., Illumina's senior vice president of corporate development and general manager of enterprise informatics will join the Twist Bioscience board of directors. Naclerio joins Rob Chess, chairman of the board of Nektar Therapeutics; Paul Conley, Ph.D., managing director of Paladin Capital Group; Keith Crandell, co-founder and managing director of ARCH Venture Partners; Fred Craves, Ph.D., founder and managing director of Bay City Capital; Bill Banyai, Ph.D., chief operating officer at Twist Bioscience; and Emily Leproust, Ph.D., chief executive officer of Twist Bioscience, on the board of directors.

"Twist Bioscience has developed a unique method of mass producing high quality DNA fragments and synthetic genes at very low cost utilizing silicon wafer manufacturing techniques," said Naclerio. "The ability to 'write' genes as easily as our sequencers can 'read'

genes will further accelerate the pace of life science research and could enable entirely new applications."

ABOUT TWIST BIOSCIENCE

At Twist Bioscience, our expertise is synthetic DNA. We have developed a proprietary semiconductor-based synthetic DNA manufacturing process featuring a 10,000-well silicon platform capable of producing synthetic biology tools, such as oligonucleotides, genes, pathways, chassis and genomes. By synthesizing DNA on silicon instead of on traditional 96-well plastic plates, our platform overcomes the current inefficiencies of synthetic DNA production, and enables cost-effective, rapid, high-quality and high throughput synthetic gene production. The Twist Bioscience platform has the potential to greatly accelerate the development of personalized medicine, sustainable chemical production, improved agriculture production as well as new applications such as in vivo diagnostics, biodetection and data storage. For more information, please visit www.twistbioscience.com. Twist Bioscience is on Twitter. Sign up to follow our Twitter feed @TwistBioscience at https://twitter.com/TwistBioscience

Contacts

Investor Contact

Maeve Conneighton | Argot Partners
T 212-600-1902 | **E** maeve@argotpartners.com

Media Contact

Angela Bitting | Twist Bioscience
T 925-202-6211 | **E** media@twistbioscience.com